Search - tctmd.com

Displaying 561 - 580 of 684

Sort: Relevancy | Date

Presentation TCT 2015

Big Data: Opportunities and Challenges 1 FDA Perspectives

Presenter: Roxana Mehran, John C Laschinger

October 13, 2015

Presentation TCT 2015

Is the Answer Pragmatic/Simple Trials? Are They Really So Simple?

Presenter: Roxana Mehran, Robert A. Harrington

October 13, 2015

Presentation TCT 2015

Life After the RIBS Trials: A Critical Overview of the Data and Implications for Clinical Practice

Presenter: Juan F. Granada, Bruno Scheller, Fernando Alfonso

October 13, 2015

Presentation TCT 2015

Keynote Lecture 3: Single-Center vs Multicenter Trials Pros, Cons, and Integration Into Evidence

Presenter: Ajay J. Kirtane, Roxana Mehran, Sanjay Kaul

October 12, 2015

Presentation TCT 2015

HOT TOPIC 6: Importance of Evaluating Competing and Recurrent Events Within Clinical Trials Clinician/Trialist Perspective

Presenter: Ajay J. Kirtane, Roxana Mehran, Robert A. Harrington

October 12, 2015

Presentation TCT 2015

HOT TOPIC 6: Importance of Evaluating Competing and Recurrent Events Within Clinical Trials Statistical Perspective

Presenter: Ajay J. Kirtane, Roxana Mehran, Eugene H. Blackstone

October 12, 2015

Presentation TCT 2015

Keynote Lecture 2: The Case for (and the Arguments Against) Moving Quality-of-Life Assessment Front and Center in Clinical Trials

Presenter: Ajay J. Kirtane, Roxana Mehran, John A. Spertus

October 12, 2015

Presentation TCT 2015

HOT TOPIC 3: How Should Trials Be Interpreted When Technology Has Moved Faster Than the Results? FOCUS on SYNTAX, COURAGE, and FREEDOM Clinicians Perspective

Presenter: Bernard J. Gersh, William S. Weintraub, Ajay J. Kirtane

October 12, 2015

Presentation TCT 2015

HOT TOPIC 3: How Should Trials Be Interpreted When Technology Has Moved Faster Than the Results? FOCUS on SYNTAX, COURAGE, and FREEDOM Guideline Perspective

Presenter: Bernard J. Gersh, William S. Weintraub, Patrick T. O'Gara

October 12, 2015

Presentation TCT 2015

HOT TOPIC 1: Should Small Randomized Trials Be Practice Changing? FOCUS on PRAMI and WOEST Clinician's Perspective

Presenter: Bernard J. Gersh, William S. Weintraub, Eric R. Bates

October 12, 2015

Presentation TCT 2015

HOT TOPIC 1: Should Small Randomized Trials Be Practice Changing? FOCUS on PRAMI and WOEST Trialist/Guideline Perspective

Presenter: Bernard J. Gersh, William S. Weintraub, John A. Bittl

October 12, 2015

Presentation TCT 2015

A Prospective Randomized Trial of Transradial vs Transfemoral Access in Patients Undergoing Coronary Angiography and Intervention

Presenter: Shigeru Saito, Gregg W. Stone, Ron Waksman, Shigeru Saito

October 12, 2015

Presentation TCT 2015

ABSORB China: A Prospective Randomized Trial of an Everolimus-Eluting Bioresorbable Scaffold vs an Everolimus-Eluting Metallic Stent in Patients With Coronary Artery Disease

Presenter: Run-Lin Gao, Gregg W. Stone, Ron Waksman, Run-Lin Gao

October 12, 2015

Presentation TCT 2015

ABSORB III: A Prospective Randomized Trial of an Everolimus-Eluting Bioresorbable Scaffold vs an Everolimus-Eluting Metallic Stent in Patients With Coronary Artery Disease

Presenter: Gregg W. Stone, Gregg W. Stone, Ron Waksman, Dean J. Kereiakes

October 12, 2015

Presentation TCT 2015

From SYMPLICITY HTN-3 to Ongoing Renal Denervation Studies: What Answers Can We Expect (and Not Expect) From the Ongoing RDN Studies?

Presenter: Ori Ben-Yehuda, Ajay J. Kirtane

October 11, 2015

Presentation TCT 2015

Updates From the PARTNER Trials 2: Reports From Selected Substudies

Presenter: Samir R. Kapadia, Jeffrey J. Popma, Darshan Doshi

October 11, 2015

Presentation TCT 2015

Updates From the PARTNER Trials 1: Follow-up From the Inoperable and High-Risk Subgroups

Presenter: Samir R. Kapadia, Jeffrey J. Popma

October 11, 2015

Presentation TCT 2015

From WOEST, DAPT, and PEGASUS to GLOBAL LEADERS and TWILIGHT: What Answers Can We Expect (and Not Expect) From GLOBAL LEADERS and TWILIGHT?

Presenter: Ori Ben-Yehuda, Ajay J. Kirtane, Roxana Mehran

October 11, 2015

Presentation TCT 2015

From PRAMI, CvLPRIT, and Other Studies to COMPLETE: What Answers Can We Expect (and Not Expect) From COMPLETE?

Presenter: Ori Ben-Yehuda, Ajay J. Kirtane, Shamir R. Mehta

October 11, 2015

Presentation TCT 2015

From SYNTAX to EXCEL: What Answers Can We Expect (and Not Expect) From EXCEL?

Presenter: Ori Ben-Yehuda, Ajay J. Kirtane, Patrick W. Serruys

October 11, 2015

Advertisement

Big Data: Opportunities and Challenges 1 FDA Perspectives

Is the Answer Pragmatic/Simple Trials? Are They Really So Simple?

Life After the RIBS Trials: A Critical Overview of the Data and Implications for Clinical Practice

Keynote Lecture 3: Single-Center vs Multicenter Trials Pros, Cons, and Integration Into Evidence

HOT TOPIC 6: Importance of Evaluating Competing and Recurrent Events Within Clinical Trials Clinician/Trialist Perspective

HOT TOPIC 6: Importance of Evaluating Competing and Recurrent Events Within Clinical Trials Statistical Perspective

Keynote Lecture 2: The Case for (and the Arguments Against) Moving Quality-of-Life Assessment Front and Center in Clinical Trials

HOT TOPIC 3: How Should Trials Be Interpreted When Technology Has Moved Faster Than the Results? FOCUS on SYNTAX, COURAGE, and FREEDOM Clinicians Perspective

HOT TOPIC 3: How Should Trials Be Interpreted When Technology Has Moved Faster Than the Results? FOCUS on SYNTAX, COURAGE, and FREEDOM Guideline Perspective

HOT TOPIC 1: Should Small Randomized Trials Be Practice Changing? FOCUS on PRAMI and WOEST Clinician's Perspective

HOT TOPIC 1: Should Small Randomized Trials Be Practice Changing? FOCUS on PRAMI and WOEST Trialist/Guideline Perspective

A Prospective Randomized Trial of Transradial vs Transfemoral Access in Patients Undergoing Coronary Angiography and Intervention

ABSORB China: A Prospective Randomized Trial of an Everolimus-Eluting Bioresorbable Scaffold vs an Everolimus-Eluting Metallic Stent in Patients With Coronary Artery Disease

ABSORB III: A Prospective Randomized Trial of an Everolimus-Eluting Bioresorbable Scaffold vs an Everolimus-Eluting Metallic Stent in Patients With Coronary Artery Disease

From SYMPLICITY HTN-3 to Ongoing Renal Denervation Studies: What Answers Can We Expect (and Not Expect) From the Ongoing RDN Studies?

Updates From the PARTNER Trials 2: Reports From Selected Substudies

Updates From the PARTNER Trials 1: Follow-up From the Inoperable and High-Risk Subgroups

From WOEST, DAPT, and PEGASUS to GLOBAL LEADERS and TWILIGHT: What Answers Can We Expect (and Not Expect) From GLOBAL LEADERS and TWILIGHT?

From PRAMI, CvLPRIT, and Other Studies to COMPLETE: What Answers Can We Expect (and Not Expect) From COMPLETE?

From SYNTAX to EXCEL: What Answers Can We Expect (and Not Expect) From EXCEL?

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content